Managing Unique Toxicities, A Case Based Discussion, an Industry Supported Symposium at ESGO 2023

Activity Overview

The GOG Foundation, Inc., GOG Partners and ImmunoGen, Inc., welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to register for the Managing Unique Toxicities, A Case Based Discussion, an Industry Supported Symposium at the ESGO 2023 Congress in Istanbul, Turkey.

In this program, we will follow a patient who is receiving mirvetuximab soravtansine and review the efficacy evidence for use of this agent in the platinum resistant setting.  The panel of experts will also discuss how to mitigate common treatment related toxicities and adverse events to best maintain dose optimization for patients receiving this drug.  The faculty will then discuss and engage the audience on a patient’s experience throughout treatment.

This symposium was developed by The GOG Foundation, Inc. in partnership with Immunogen, Inc.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

    • Identify risk factors related to adverse reactions associated with ADCs
    • Educate on specific cases and determine best practices when treating patients
    • Determine how to integrate treatment options into clinical practice

Moderator


Dr. Kathleen Moore

Faculty


Dr. Ana Oaknin

Dr. Toon Van Gorp, MD, PhD

Dr. Antonio González-Martin 

Agenda & Presentation Materials

Managing Unique Toxicities, A Case Based Discussion, an Industry Supported Symposium at the ESGO 2023 Congress

Presented on Friday, September 29, 2023 from 1:00 pm – 2:00 pm local Istanbul time.

Register Today

1:00 pm – 1:05 pm
Welcome & Introduction
Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
1:05 pm – 1:15 pm
Efficacy Data of Soraya and Mirasol
Ana Oaknin, MD, Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, Barcelona, Spain
1:15 pm – 1:20 pm
Patient Case Introduction
Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
1:20 pm – 1:35 pm
Patient Experience: Mid-Case Ocular Adverse Reactions
Toon Van Gorp, MD, PhD, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium
1:35 pm – 1:45 pm
Patient Experience: The Overall and Unique Toxicities
Antonio González-Martin, MD, Clínica Universitaria de Navarra in Madrid (CUN-Madrid), Madrid, Spain
1:45 pm – 2:00 pm
Open Discussion, Audience Q&A
All Faculty